Okuma Y, Kubota K, Shimokawa M, Hashimoto K, et al. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2024;10:43-51.
PMID: 37991747